DHR vs RGEN vs A Stock Comparison

Danaher, Repligen and Agilent Technologies Prices as of Oct 26, 2026 Peers: Industry group
DHR Danaher Corp /De/
$232.95 +3.7% 1M +4.5% 1Y
Market cap
$163.62B
P/E
40.9x
Revenue (TTM)
$25.11B
Div. yield
–
Life Sciences Tools Healthcare
3 wins
RGEN Repligen Corp
$180.17 -5.0% 1M +8.3% 1Y
Market cap
$9.92B
P/E
238.7x
Revenue (TTM)
$785.10M
Div. yield
–
Life Sciences Tools Healthcare
3 wins
A Agilent Technologies, Inc.
$175.96 +1.8% 1M +18.9% 1Y
Market cap
$50.15B
P/E
34.8x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
5 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 5 of the 12 questions below (Agilent Technologies 5, Danaher 3, Repligen 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRRGENALeader
Larger companyMarket capitalisation $163.62B $9.92B $50.15B DHR
Cheaper on earningsLower P/E, profitable companies only 40.9x 238.7x 34.8x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.6x 92.9x 26.9x DHR
Faster revenue growthRevenue growth, trailing twelve months +4.6% +16.5% +8.6% RGEN
More profitableNet margin, trailing twelve months 15.9% 5.3% 19.5% A
Better return on capitalReturn on invested capital 5.7% 1.9% 13.1% A
Less leveragedLower net debt / EBITDA 2.9x -1.6x 1.1x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +4.5% +8.3% +18.9% A
Better 5-year returnAnnualised price return, 5 years -5.3%/yr -7.8%/yr +2.5%/yr A
Less volatileAnnualised volatility, 1 year 30.7% 46.3% 32.4% DHR
Higher overall scoreMean of the five percentile scores vs peers 59/100 66/100 62/100 RGEN

Percentile Scorecard

DHRRGENA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRRGENA
Valuation 67 #75 of 228 54 #105 of 228 58 #97 of 228
Growth 21 #176 of 221 56 #98 of 221 36 #141 of 221
Profitability 88 #26 of 208 71 #61 of 208 91 #20 of 208
Financial Health 46 #130 of 239 80 #48 of 239 55 #108 of 239
Shareholder Returns 76 #34 of 137 68 #44 of 137 71 #40 of 137
Overall 59 66 62
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • RGEN ranked among 248 companies in Medical Devices and Diagnostics
  • A ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRRGENASPY
1 month +3.7%-5.0%+1.8% -0.8%
3 months +18.5%+37.5%+27.6% +3.5%
6 months +29.0%+52.3%+52.2% +7.0%
Year to date +1.8%+10.0%+29.3% +12.2%
1 year +4.5%+8.3%+18.9% +13.0%
3 years +24.0%+50.7%+71.2% +86.3%
3 years, per year +7.4%+14.7%+19.6% +23.1%
5 years -23.7%-33.5%+13.3% +68.6%
5 years, per year -5.3%-7.8%+2.5% +11.0%
10 years +199.7%+525.2%+305.7% +258.0%
10 years, per year +11.6%+20.1%+15.0% +13.6%

Risk

MeasureDHRRGENASPY
Volatility, 1Y 30.7%46.3%32.4% 12.7%
Downside volatility, 1Y 31.8%46.8%27.5% 12.7%
Beta vs S&P 500, 1Y 0.451.220.88 1.00
Return / volatility, 1Y 0.150.180.58 1.02
Max drawdown, 5Y -50.8%-66.2%-39.6% -25.4%
From 52-week high -3.8%-7.4%-1.0% -1.8%
52-week high $242.05$194.57$177.72 $779.14
52-week low $161.91$102.87$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRRGENA
P/E now vs peer median 41.0xmedian 30.6x 244.7xmedian 30.6x 34.5xmedian 30.6x
P/S now vs peer median 6.5xmedian 3.0x 12.9xmedian 3.0x 6.7xmedian 3.0x
EV/EBITDA now vs peer median 24.3xmedian 17.5x 61.6xmedian 17.5x 27.1xmedian 17.5x
P/FCF now vs peer median 30.0xmedian 23.3x 90.8xmedian 23.3x 39.2xmedian 23.3x
P/B now vs peer median 3.1xmedian 2.4x 4.8xmedian 2.4x 6.7xmedian 2.4x
PEG now vs peer median -3.28median 0.87 -8.04median 0.87 3.51median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRRGENA
Revenue $25.11B $785.10M $7.37B
Gross profit $14.69B $422.67M $3.97B
Operating income $5.13B $64.61M $1.64B
Net income $4.00B $41.54M $1.44B
Free cash flow $5.47B $111.97M $1.27B
R&D $1.62B $56.17M $485.00M
EPS (diluted) $5.66 $0.73 $5.09
Cash & equivalents $4.35B $606.78M $1.76B
Total debt $26.56B $551.05M $3.95B
Shares (diluted) 707.60M 56.64M 283.00M
Enterprise value $147.42B $6.81B $43.03B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRRGENA
P/E 41.0x 244.7x 34.5x
P/FCF 30.0x 90.8x 39.2x
P/Operating cash flow 24.7x 75.4x 30.8x
P/S 6.5x 12.9x 6.7x
P/B 3.1x 4.8x 6.7x
P/Tangible book 5.2x 5.8x 7.7x
EV/EBITDA 24.3x 61.6x 27.1x
EV/EBIT 36.3x 153.3x 31.6x
EV/Revenue 7.4x 12.6x 7.0x
EV/FCF 34.0x 88.5x 40.9x
EV/Operating cash flow 28.0x 73.5x 32.2x
PEG (3Y EPS CAGR) -3.28 -8.04 3.51

Growth

14 metrics
MetricDHRRGENA
Revenue growth (1Y) 4.6% 16.5% 8.6%
Revenue CAGR (3Y) -0.5% 3.3% 1.8%
Gross profit growth (1Y) 2.6% 40.6% 11.2%
Gross profit CAGR (3Y) -0.9% 4.2% 3.7%
Operating income growth (1Y) 16.1% 370.8% 13.5%
Operating income CAGR (3Y) -7.1% -21.7% 5.1%
Net income growth (1Y) 17.3% 400.4% 18.0%
Net income CAGR (3Y) -14.3% -30.6% 8.3%
EPS growth (1Y) 19.2% 399.7% 18.9%
EPS CAGR (3Y) -12.5% -30.4% 9.8%
Operating cash flow growth (1Y) 7.6% 2.1% 7.6%
Operating cash flow CAGR (3Y) -7.6% -3.2% -1.9%
Free cash flow growth (1Y) 12.4% 2.8% 16.5%
Free cash flow CAGR (3Y) -9.0% 3.9% -3.7%

Profitability

14 metrics
MetricDHRRGENA
Gross margin 58.5% 53.8% 53.8%
EBITDA margin 30.5% 20.5% 25.9%
Operating margin 20.4% 8.2% 22.2%
Pretax margin 19.0% 6.6% 22.5%
Net margin 15.9% 5.3% 19.5%
FCF margin 21.8% 14.3% 17.2%
Operating cash flow margin 26.4% 17.2% 21.8%
Return on equity 7.6% 2.0% 19.9%
Return on assets 4.5% 1.4% 10.7%
Return on invested capital 5.7% 1.9% 13.1%
Return on capital employed 6.4% 2.3% 14.6%
Asset turnover 0.3x 0.3x 0.5x
Cash conversion (OCF / net income) 1.7x 3.2x 1.1x
Stock comp / revenue 1.2% 4.2% 1.8%

Financial Health

11 metrics
MetricDHRRGENA
Debt / assets 28.8% 18.7% 28.3%
Debt / equity 0.5x 0.3x 0.5x
Net debt / EBITDA 2.9x -1.6x 1.1x
Debt / FCF 4.9x 4.9x 3.1x
Liabilities / assets 43.1% 28.4% 47.3%
Equity / assets 56.9% 71.6% 52.7%
Interest coverage 17.6x 2.9x 15.5x
Current ratio 1.7x 9.1x 2.1x
Quick ratio 1.0x 7.3x 1.4x
Cash ratio 0.5x 6.1x 0.8x
Altman Z-score 3.72 8.27 5.82

Shareholder Returns

7 metrics
MetricDHRRGENA
Dividend yield 0.7% – 0.6%
Net buyback yield 1.8% 0.0% 0.6%
Shareholder yield 2.4% 0.0% 1.2%
Payout ratio (earnings) – – 19.9%
Payout ratio (FCF) – – 22.6%
Dividend growth (1Y) – – 2.1%
Dividend CAGR (3Y) – – 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRRGENA
Forward P/E 25.6xFY2026 92.9xFY2026 26.9xFY2026
EPS, next fiscal year $9.11FY2026 $1.94FY2026 $6.54FY2026
EPS growth, next FY +16.8%FY2026 +13.5%FY2026 +17.0%FY2026
EPS growth, the year after +8.0% +29.4% +0.3%
Revenue, next fiscal year $27.01BFY2026 $773.94MFY2026 $7.87BFY2026
Revenue growth, next FY +9.9%FY2026 +4.8%FY2026 +15.3%FY2026
Revenue growth, the year after -1.9% +35.9% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRRGENA
Held by institutions 81.9% 100.0% 92.6%
Institutions holding 2,115 482 1,122
Change in shares held, QoQ +1.1% +1.2% +3.2%
Institutions buying 837 272 599
Institutions selling 1,015 141 350
Buyers to sellers 0.82 1.93 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRRGENA
DHR 1.00 0.63 0.60
RGEN 0.63 1.00 0.62
A 0.60 0.62 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, RGEN and A?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $163.62B, Repligen (RGEN) $9.92B, Agilent Technologies (A) $50.15B.

Which stock is cheaper, DHR, RGEN and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Danaher (DHR) 40.9x, Repligen (RGEN) 238.7x, Agilent Technologies (A) 34.8x). On next year's consensus earnings, Danaher (DHR) is cheapest (Danaher (DHR) 25.6x, Repligen (RGEN) 92.9x, Agilent Technologies (A) 26.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Danaher (DHR) +4.6%, Repligen (RGEN) +16.5%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Danaher (DHR) 15.9%, Repligen (RGEN) 5.3%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Danaher (DHR) 5.7%, Repligen (RGEN) 1.9%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Danaher (DHR) +4.5%, Repligen (RGEN) +8.3%, Agilent Technologies (A) +18.9%. Over five years, Agilent Technologies (A) compounded fastest (Danaher (DHR) -5.3%/yr, Repligen (RGEN) -7.8%/yr, Agilent Technologies (A) +2.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Danaher (DHR) 0.00%, Repligen (RGEN) 0.00%, Agilent Technologies (A) 0.01%. Danaher (DHR) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.7%, Repligen (RGEN) 46.3%, Agilent Technologies (A) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, RGEN and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.